Immune cells engineered to fight lymphoma enter human testing
NCT ID NCT07073833
First seen Jul 02, 2026 · Last updated Jul 02, 2026
Summary
This early-stage trial tests a new treatment called IBR900, made from natural killer (NK) cells, for people with a type of blood cancer called CD20-positive B-cell non-Hodgkin lymphoma that has come back or not responded to prior therapy. The study has two parts: first, finding the safest dose of IBR900 alone, then testing it combined with a standard antibody drug (rituximab). The goal is to see if this cell therapy is safe and shows signs of shrinking tumors.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
Active substance
IBR900 cell injection (NK cells) and rituximab (CD20 antibody)
What this could lead to
If successful, this could offer a new treatment option for patients with hard-to-treat B-cell lymphoma that has not responded to standard therapies.
What could go wrong
This is an early Phase 1 trial with only 40 participants, so safety and dosing are still being determined. The treatment may not work for everyone and could cause side effects.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for RELAPSED/REFRACTORY B-CELL NON-HODGKIN LYMPHOMA are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
More trials for these conditions
Other studies related to the condition(s) this trial covers.
- CD19/22 CAR-T + PD-1 Inhibitor for Lymphoma (NCT04539444)
- Study on bispecific antibody therapy for lymphom NCT07614035
- JL19001 for Advanced Solid Tumors or Lymphoma (NCT07603479)
- CD19/CD20 CAR-T Trial for B-Cell Cancers (NCT07002112)
- CD19 t-haNK for B-Cell NHL Trial (NCT06334991)
- ATA3219 CAR-T for Lymphoma Trial (NCT06256484)
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Study contacts
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
Locations
-
Shanghai Rui Jin Hospital, Shanghai Jiao Tong University School of Medicine
RECRUITINGShanghai, China
Contact Phone: •••-•••-•••• Email: •••••@•••••
-
The First Affiliated Hospital, School of Medicine, Zhejiang University
RECRUITINGHangzhou, Zhejiang, China
Contact Phone: •••-•••-•••• Email: •••••@•••••